nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—prostate cancer—testicular cancer	0.182	0.39	CtDrD
Docetaxel—ovarian cancer—testicular cancer	0.158	0.338	CtDrD
Docetaxel—lung cancer—testicular cancer	0.127	0.273	CtDrD
Docetaxel—TUBB3—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB2A—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB6—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB4A—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB2B—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB8—Vinblastine—testicular cancer	0.0257	0.0667	CbGbCtD
Docetaxel—TUBB1—Vinblastine—testicular cancer	0.0215	0.0558	CbGbCtD
Docetaxel—TUBB4B—Vinblastine—testicular cancer	0.0215	0.0558	CbGbCtD
Docetaxel—TUBB—Vinblastine—testicular cancer	0.0215	0.0558	CbGbCtD
Docetaxel—ABCC10—Etoposide—testicular cancer	0.0148	0.0384	CbGbCtD
Docetaxel—ABCC1—Dactinomycin—testicular cancer	0.0101	0.0263	CbGbCtD
Docetaxel—ABCC10—Doxorubicin—testicular cancer	0.0101	0.0262	CbGbCtD
Docetaxel—ABCC10—Methotrexate—testicular cancer	0.00976	0.0254	CbGbCtD
Docetaxel—ABCC1—Epirubicin—testicular cancer	0.00732	0.019	CbGbCtD
Docetaxel—ABCG2—Dactinomycin—testicular cancer	0.00677	0.0176	CbGbCtD
Docetaxel—ABCC1—Vinblastine—testicular cancer	0.00633	0.0165	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0059	0.0153	CbGbCtD
Docetaxel—CYP3A7—Ifosfamide—testicular cancer	0.0059	0.0153	CbGbCtD
Docetaxel—ABCC1—Etoposide—testicular cancer	0.00571	0.0148	CbGbCtD
Docetaxel—CYP1B1—Doxorubicin—testicular cancer	0.00548	0.0142	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—testicular cancer	0.00545	0.0142	CbGbCtD
Docetaxel—ABCC2—Carboplatin—testicular cancer	0.00503	0.0131	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—testicular cancer	0.0048	0.0125	CbGbCtD
Docetaxel—ABCC2—Vinblastine—testicular cancer	0.00469	0.0122	CbGbCtD
Docetaxel—ABCG2—Carboplatin—testicular cancer	0.00455	0.0118	CbGbCtD
Docetaxel—CYP3A5—Ifosfamide—testicular cancer	0.00443	0.0115	CbGbCtD
Docetaxel—ABCC2—Cisplatin—testicular cancer	0.0043	0.0112	CbGbCtD
Docetaxel—ABCC2—Etoposide—testicular cancer	0.00422	0.011	CbGbCtD
Docetaxel—ABCC1—Doxorubicin—testicular cancer	0.00389	0.0101	CbGbCtD
Docetaxel—ABCG2—Cisplatin—testicular cancer	0.00389	0.0101	CbGbCtD
Docetaxel—ABCG2—Etoposide—testicular cancer	0.00382	0.00992	CbGbCtD
Docetaxel—ABCC1—Methotrexate—testicular cancer	0.00377	0.00979	CbGbCtD
Docetaxel—ABCC2—Doxorubicin—testicular cancer	0.00288	0.00748	CbGbCtD
Docetaxel—ABCC2—Methotrexate—testicular cancer	0.00279	0.00725	CbGbCtD
Docetaxel—ABCG2—Doxorubicin—testicular cancer	0.0026	0.00677	CbGbCtD
Docetaxel—ABCG2—Methotrexate—testicular cancer	0.00252	0.00655	CbGbCtD
Docetaxel—ABCB1—Dactinomycin—testicular cancer	0.00244	0.00634	CbGbCtD
Docetaxel—KIF11—embryo—testicular cancer	0.00221	0.0675	CbGeAlD
Docetaxel—CYP3A5—Etoposide—testicular cancer	0.00212	0.0055	CbGbCtD
Docetaxel—CYP3A4—Ifosfamide—testicular cancer	0.00173	0.00448	CbGbCtD
Docetaxel—ABCB1—Vinblastine—testicular cancer	0.00153	0.00397	CbGbCtD
Docetaxel—ABCB1—Cisplatin—testicular cancer	0.0014	0.00364	CbGbCtD
Docetaxel—ABCB1—Etoposide—testicular cancer	0.00138	0.00358	CbGbCtD
Docetaxel—KIF11—female gonad—testicular cancer	0.00122	0.0372	CbGeAlD
Docetaxel—KIF11—Teniposide—Etoposide—testicular cancer	0.00118	1	CbGdCrCtD
Docetaxel—KIF11—testis—testicular cancer	0.00108	0.033	CbGeAlD
Docetaxel—MAP4—embryo—testicular cancer	0.00102	0.0311	CbGeAlD
Docetaxel—GHRHR—G alpha (s) signalling events—INSL3—testicular cancer	0.000974	0.0694	CbGpPWpGaD
Docetaxel—ABCB1—Doxorubicin—testicular cancer	0.000939	0.00244	CbGbCtD
Docetaxel—CYP3A4—Vinblastine—testicular cancer	0.000916	0.00238	CbGbCtD
Docetaxel—ABCB1—Methotrexate—testicular cancer	0.00091	0.00236	CbGbCtD
Docetaxel—CYP3A4—Etoposide—testicular cancer	0.000825	0.00214	CbGbCtD
Docetaxel—MAP2—embryo—testicular cancer	0.000803	0.0245	CbGeAlD
Docetaxel—KIF11—lymph node—testicular cancer	0.000785	0.0239	CbGeAlD
Docetaxel—MAP2—seminal vesicle—testicular cancer	0.000754	0.023	CbGeAlD
Docetaxel—TUBB8—testis—testicular cancer	0.000731	0.0223	CbGeAlD
Docetaxel—MAP4—gonad—testicular cancer	0.000692	0.0211	CbGeAlD
Docetaxel—MAP2—LKB1 signaling events—STK11—testicular cancer	0.000645	0.0459	CbGpPWpGaD
Docetaxel—MAPT—testis—testicular cancer	0.000635	0.0194	CbGeAlD
Docetaxel—BCL2—gonad—testicular cancer	0.000629	0.0192	CbGeAlD
Docetaxel—TUBB4A—embryo—testicular cancer	0.000621	0.0189	CbGeAlD
Docetaxel—TUBB2B—seminal vesicle—testicular cancer	0.000563	0.0172	CbGeAlD
Docetaxel—CYP3A4—Doxorubicin—testicular cancer	0.000563	0.00146	CbGbCtD
Docetaxel—MAP4—female gonad—testicular cancer	0.000563	0.0172	CbGeAlD
Docetaxel—MAP2—gonad—testicular cancer	0.000545	0.0166	CbGeAlD
Docetaxel—TUBB—seminal vesicle—testicular cancer	0.000533	0.0163	CbGeAlD
Docetaxel—TUBB2A—seminal vesicle—testicular cancer	0.00053	0.0162	CbGeAlD
Docetaxel—TUBB6—seminal vesicle—testicular cancer	0.000523	0.016	CbGeAlD
Docetaxel—BCL2—female gonad—testicular cancer	0.000511	0.0156	CbGeAlD
Docetaxel—EGFR—female gonad—testicular cancer	0.000505	0.0154	CbGeAlD
Docetaxel—TUBB3—testis—testicular cancer	0.000499	0.0152	CbGeAlD
Docetaxel—MAP4—testis—testicular cancer	0.000499	0.0152	CbGeAlD
Docetaxel—TUBB1—testis—testicular cancer	0.000488	0.0149	CbGeAlD
Docetaxel—TUBB4B—embryo—testicular cancer	0.000484	0.0148	CbGeAlD
Docetaxel—MAPT—lymph node—testicular cancer	0.00046	0.014	CbGeAlD
Docetaxel—ABCC10—seminal vesicle—testicular cancer	0.000458	0.014	CbGeAlD
Docetaxel—TUBB4B—seminal vesicle—testicular cancer	0.000455	0.0139	CbGeAlD
Docetaxel—BCL2—testis—testicular cancer	0.000454	0.0138	CbGeAlD
Docetaxel—EGFR—testis—testicular cancer	0.000448	0.0137	CbGeAlD
Docetaxel—MAP2—female gonad—testicular cancer	0.000443	0.0135	CbGeAlD
Docetaxel—TUBB4A—gonad—testicular cancer	0.000421	0.0129	CbGeAlD
Docetaxel—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00041	0.0292	CbGpPWpGaD
Docetaxel—TUBB2B—gonad—testicular cancer	0.000407	0.0124	CbGeAlD
Docetaxel—MAP2—testis—testicular cancer	0.000393	0.012	CbGeAlD
Docetaxel—TUBB6—gonad—testicular cancer	0.000378	0.0115	CbGeAlD
Docetaxel—MAP4—lymph node—testicular cancer	0.000362	0.011	CbGeAlD
Docetaxel—MAPT—LKB1 signaling events—STK11—testicular cancer	0.000361	0.0257	CbGpPWpGaD
Docetaxel—GHRHR—GPCR ligand binding—INSL3—testicular cancer	0.000354	0.0252	CbGpPWpGaD
Docetaxel—TUBB4A—female gonad—testicular cancer	0.000342	0.0104	CbGeAlD
Docetaxel—SLC22A7—testis—testicular cancer	0.00034	0.0104	CbGeAlD
Docetaxel—ABCC10—gonad—testicular cancer	0.000331	0.0101	CbGeAlD
Docetaxel—TUBB2B—female gonad—testicular cancer	0.000331	0.0101	CbGeAlD
Docetaxel—BCL2—lymph node—testicular cancer	0.000329	0.01	CbGeAlD
Docetaxel—TUBB4B—gonad—testicular cancer	0.000329	0.01	CbGeAlD
Docetaxel—EGFR—lymph node—testicular cancer	0.000325	0.00991	CbGeAlD
Docetaxel—ABCC1—seminal vesicle—testicular cancer	0.000324	0.00989	CbGeAlD
Docetaxel—TUBB—female gonad—testicular cancer	0.000313	0.00955	CbGeAlD
Docetaxel—TUBB2A—female gonad—testicular cancer	0.000311	0.0095	CbGeAlD
Docetaxel—TUBB6—female gonad—testicular cancer	0.000307	0.00937	CbGeAlD
Docetaxel—TUBB4A—testis—testicular cancer	0.000304	0.00927	CbGeAlD
Docetaxel—TUBB2B—testis—testicular cancer	0.000293	0.00896	CbGeAlD
Docetaxel—MAP2—lymph node—testicular cancer	0.000285	0.00869	CbGeAlD
Docetaxel—TUBB—testis—testicular cancer	0.000278	0.00847	CbGeAlD
Docetaxel—TUBB2A—testis—testicular cancer	0.000276	0.00843	CbGeAlD
Docetaxel—TUBB6—testis—testicular cancer	0.000272	0.00831	CbGeAlD
Docetaxel—ABCC10—female gonad—testicular cancer	0.000269	0.00821	CbGeAlD
Docetaxel—ABCG2—seminal vesicle—testicular cancer	0.000268	0.00818	CbGeAlD
Docetaxel—TUBB4B—female gonad—testicular cancer	0.000267	0.00815	CbGeAlD
Docetaxel—CYP1B1—gonad—testicular cancer	0.00026	0.00794	CbGeAlD
Docetaxel—MAPT—Kit receptor signaling pathway—KITLG—testicular cancer	0.00026	0.0185	CbGpPWpGaD
Docetaxel—ABCC10—testis—testicular cancer	0.000239	0.00728	CbGeAlD
Docetaxel—TUBB4B—testis—testicular cancer	0.000237	0.00723	CbGeAlD
Docetaxel—TUBB4A—lymph node—testicular cancer	0.00022	0.00672	CbGeAlD
Docetaxel—TUBB2B—lymph node—testicular cancer	0.000213	0.00649	CbGeAlD
Docetaxel—CYP1B1—female gonad—testicular cancer	0.000211	0.00645	CbGeAlD
Docetaxel—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00021	0.0149	CbGpPWpGaD
Docetaxel—TUBB—lymph node—testicular cancer	0.000201	0.00614	CbGeAlD
Docetaxel—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000201	0.0143	CbGpPWpGaD
Docetaxel—TUBB2A—lymph node—testicular cancer	0.0002	0.00611	CbGeAlD
Docetaxel—GHRHR—GPCR downstream signaling—INSL3—testicular cancer	0.0002	0.0142	CbGpPWpGaD
Docetaxel—TUBB6—lymph node—testicular cancer	0.000197	0.00603	CbGeAlD
Docetaxel—ABCC2—testis—testicular cancer	0.000192	0.00585	CbGeAlD
Docetaxel—ABCC1—female gonad—testicular cancer	0.00019	0.00581	CbGeAlD
Docetaxel—BCL2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000188	0.0134	CbGpPWpGaD
Docetaxel—CYP1B1—testis—testicular cancer	0.000188	0.00572	CbGeAlD
Docetaxel—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000187	0.0133	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—INSL3—testicular cancer	0.000181	0.0129	CbGpPWpGaD
Docetaxel—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.000179	0.0128	CbGpPWpGaD
Docetaxel—SLCO1B3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000177	0.0126	CbGpPWpGaD
Docetaxel—MAPT—Kit receptor signaling pathway—KIT—testicular cancer	0.000177	0.0126	CbGpPWpGaD
Docetaxel—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000176	0.0125	CbGpPWpGaD
Docetaxel—ABCC10—lymph node—testicular cancer	0.000173	0.00528	CbGeAlD
Docetaxel—TUBB4B—lymph node—testicular cancer	0.000172	0.00524	CbGeAlD
Docetaxel—EGFR—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000171	0.0122	CbGpPWpGaD
Docetaxel—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00017	0.0121	CbGpPWpGaD
Docetaxel—ABCC1—testis—testicular cancer	0.000169	0.00515	CbGeAlD
Docetaxel—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000164	0.0117	CbGpPWpGaD
Docetaxel—EGFR—Syndecan-3-mediated signaling events—FGFR3—testicular cancer	0.00016	0.0114	CbGpPWpGaD
Docetaxel—BCL2—Kit receptor signaling pathway—KITLG—testicular cancer	0.00016	0.0114	CbGpPWpGaD
Docetaxel—ABCG2—female gonad—testicular cancer	0.000157	0.00481	CbGeAlD
Docetaxel—KIF11—Adaptive Immune System—BCL10—testicular cancer	0.000157	0.0112	CbGpPWpGaD
Docetaxel—MAPT—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000151	0.0107	CbGpPWpGaD
Docetaxel—MAPT—LPA receptor mediated events—MMP2—testicular cancer	0.000147	0.0105	CbGpPWpGaD
Docetaxel—CYP3A5—female gonad—testicular cancer	0.000146	0.00446	CbGeAlD
Docetaxel—ABCB1—embryo—testicular cancer	0.000141	0.0043	CbGeAlD
Docetaxel—ABCG2—testis—testicular cancer	0.00014	0.00426	CbGeAlD
Docetaxel—ABCC2—lymph node—testicular cancer	0.000139	0.00424	CbGeAlD
Docetaxel—CYP1B1—lymph node—testicular cancer	0.000136	0.00415	CbGeAlD
Docetaxel—TUBB2B—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000133	0.00945	CbGpPWpGaD
Docetaxel—TUBB6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000133	0.00945	CbGpPWpGaD
Docetaxel—ABCB1—seminal vesicle—testicular cancer	0.000132	0.00404	CbGeAlD
Docetaxel—BCL2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000131	0.00932	CbGpPWpGaD
Docetaxel—TUBB3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000128	0.00913	CbGpPWpGaD
Docetaxel—TUBB2A—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000124	0.00884	CbGpPWpGaD
Docetaxel—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.000122	0.00872	CbGpPWpGaD
Docetaxel—ABCC1—lymph node—testicular cancer	0.000122	0.00373	CbGeAlD
Docetaxel—TUBB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000121	0.00865	CbGpPWpGaD
Docetaxel—BCL2—C-MYB transcription factor network—KITLG—testicular cancer	0.00012	0.00857	CbGpPWpGaD
Docetaxel—EGFR—Bladder Cancer—FGFR3—testicular cancer	0.000117	0.00836	CbGpPWpGaD
Docetaxel—MAPT—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00011	0.00781	CbGpPWpGaD
Docetaxel—TUBB4A—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000109	0.00776	CbGpPWpGaD
Docetaxel—BCL2—Kit receptor signaling pathway—KIT—testicular cancer	0.000109	0.00776	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—INSL3—testicular cancer	0.000107	0.00764	CbGpPWpGaD
Docetaxel—ABCG2—lymph node—testicular cancer	0.000101	0.00309	CbGeAlD
Docetaxel—TUBB4B—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.96e-05	0.0071	CbGpPWpGaD
Docetaxel—BCL2—ATF-2 transcription factor network—MMP2—testicular cancer	9.65e-05	0.00688	CbGpPWpGaD
Docetaxel—ABCB1—gonad—testicular cancer	9.56e-05	0.00292	CbGeAlD
Docetaxel—KIF11—Immune System—BCL10—testicular cancer	9.52e-05	0.00678	CbGpPWpGaD
Docetaxel—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.48e-05	0.00675	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—KITLG—testicular cancer	9.47e-05	0.00674	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	9.28e-05	0.00661	CbGpPWpGaD
Docetaxel—SLCO1B3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9e-05	0.00641	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—PRDM14—testicular cancer	8.67e-05	0.00618	CbGpPWpGaD
Docetaxel—BCL2—C-MYB transcription factor network—KIT—testicular cancer	8.21e-05	0.00585	CbGpPWpGaD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—STK11—testicular cancer	8.13e-05	0.0058	CbGpPWpGaD
Docetaxel—ABCB1—female gonad—testicular cancer	7.77e-05	0.00237	CbGeAlD
Docetaxel—NR1I2—Gene Expression—DNMT3L—testicular cancer	7.36e-05	0.00525	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—FGFR3—testicular cancer	7.04e-05	0.00501	CbGpPWpGaD
Docetaxel—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	6.98e-05	0.00497	CbGpPWpGaD
Docetaxel—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	6.97e-05	0.00497	CbGpPWpGaD
Docetaxel—ABCB1—testis—testicular cancer	6.89e-05	0.0021	CbGeAlD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	6.81e-05	0.00485	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	6.74e-05	0.0048	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	6.5e-05	0.00463	CbGpPWpGaD
Docetaxel—KIF11—Adaptive Immune System—KIT—testicular cancer	6.46e-05	0.0046	CbGpPWpGaD
Docetaxel—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.44e-05	0.00459	CbGpPWpGaD
Docetaxel—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.37e-05	0.00454	CbGpPWpGaD
Docetaxel—EGFR—PI-3K cascade—KITLG—testicular cancer	6.29e-05	0.00448	CbGpPWpGaD
Docetaxel—EGFR—PI3K/AKT activation—KITLG—testicular cancer	6.14e-05	0.00437	CbGpPWpGaD
Docetaxel—CYP1B1—Biological oxidations—HPGDS—testicular cancer	6.12e-05	0.00436	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle, Mitotic—MAD1L1—testicular cancer	6.1e-05	0.00435	CbGpPWpGaD
Docetaxel—EGFR—GAB1 signalosome—KITLG—testicular cancer	6.09e-05	0.00434	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—BCL10—testicular cancer	6.01e-05	0.00428	CbGpPWpGaD
Docetaxel—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	5.95e-05	0.00424	CbGpPWpGaD
Docetaxel—KIF11—Immune System—KITLG—testicular cancer	5.74e-05	0.00409	CbGpPWpGaD
Docetaxel—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.6e-05	0.00399	CbGpPWpGaD
Docetaxel—CYP3A7—Biological oxidations—HPGDS—testicular cancer	5.52e-05	0.00393	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.48e-05	0.00391	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—MAD1L1—testicular cancer	5.45e-05	0.00389	CbGpPWpGaD
Docetaxel—EGFR—LPA receptor mediated events—MMP2—testicular cancer	5.35e-05	0.00381	CbGpPWpGaD
Docetaxel—EGFR—AGE/RAGE pathway—MMP2—testicular cancer	5.22e-05	0.00372	CbGpPWpGaD
Docetaxel—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	5.19e-05	0.0037	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—MAD1L1—testicular cancer	5.05e-05	0.0036	CbGpPWpGaD
Docetaxel—ABCB1—lymph node—testicular cancer	4.99e-05	0.00152	CbGeAlD
Docetaxel—BCL2—Direct p53 effectors—MMP2—testicular cancer	4.83e-05	0.00344	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—STK11—testicular cancer	4.81e-05	0.00343	CbGpPWpGaD
Docetaxel—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	4.76e-05	0.00339	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—KITLG—testicular cancer	4.7e-05	0.00335	CbGpPWpGaD
Docetaxel—EGFR—PI-3K cascade—FGFR3—testicular cancer	4.67e-05	0.00333	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—MAD1L1—testicular cancer	4.62e-05	0.00329	CbGpPWpGaD
Docetaxel—EGFR—PI3K/AKT activation—FGFR3—testicular cancer	4.56e-05	0.00325	CbGpPWpGaD
Docetaxel—EGFR—GAB1 signalosome—FGFR3—testicular cancer	4.53e-05	0.00322	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—MAD1L1—testicular cancer	4.52e-05	0.00322	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—KITLG—testicular cancer	4.5e-05	0.0032	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—KITLG—testicular cancer	4.43e-05	0.00315	CbGpPWpGaD
Docetaxel—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	4.42e-05	0.00315	CbGpPWpGaD
Docetaxel—EGFR—PI-3K cascade—KIT—testicular cancer	4.29e-05	0.00306	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—BCL10—testicular cancer	4.27e-05	0.00304	CbGpPWpGaD
Docetaxel—KIF11—Immune System—FGFR3—testicular cancer	4.27e-05	0.00304	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle, Mitotic—H2AFZ—testicular cancer	4.25e-05	0.00303	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—KITLG—testicular cancer	4.23e-05	0.00301	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—KITLG—testicular cancer	4.21e-05	0.003	CbGpPWpGaD
Docetaxel—EGFR—PI3K/AKT activation—KIT—testicular cancer	4.19e-05	0.00298	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—KITLG—testicular cancer	4.19e-05	0.00298	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—KITLG—testicular cancer	4.17e-05	0.00297	CbGpPWpGaD
Docetaxel—EGFR—GAB1 signalosome—KIT—testicular cancer	4.16e-05	0.00296	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—MAD1L1—testicular cancer	4.13e-05	0.00294	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	4.11e-05	0.00292	CbGpPWpGaD
Docetaxel—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	4.06e-05	0.00289	CbGpPWpGaD
Docetaxel—CYP3A5—Biological oxidations—HPGDS—testicular cancer	3.99e-05	0.00284	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3.98e-05	0.00284	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	3.92e-05	0.00279	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	3.92e-05	0.00279	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—KITLG—testicular cancer	3.92e-05	0.00279	CbGpPWpGaD
Docetaxel—KIF11—Immune System—KIT—testicular cancer	3.92e-05	0.00279	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—KITLG—testicular cancer	3.88e-05	0.00277	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	3.85e-05	0.00274	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—KITLG—testicular cancer	3.83e-05	0.00273	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—H2AFZ—testicular cancer	3.8e-05	0.00271	CbGpPWpGaD
Docetaxel—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.77e-05	0.00269	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—KITLG—testicular cancer	3.63e-05	0.00258	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—H2AFZ—testicular cancer	3.52e-05	0.00251	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	3.49e-05	0.00249	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	3.47e-05	0.00247	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.44e-05	0.00245	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—H2AFZ—testicular cancer	3.43e-05	0.00244	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—STK11—testicular cancer	3.41e-05	0.00243	CbGpPWpGaD
Docetaxel—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	3.34e-05	0.00238	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	3.34e-05	0.00238	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—INSL3—testicular cancer	3.3e-05	0.00235	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	3.29e-05	0.00234	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—H2AFZ—testicular cancer	3.22e-05	0.0023	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	3.21e-05	0.00229	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—KITLG—testicular cancer	3.16e-05	0.00225	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—H2AFZ—testicular cancer	3.15e-05	0.00224	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—FGFR3—testicular cancer	3.14e-05	0.00224	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—FGFR3—testicular cancer	3.13e-05	0.00223	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	3.11e-05	0.00222	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—FGFR3—testicular cancer	3.1e-05	0.00221	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	3.07e-05	0.00219	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	3.05e-05	0.00217	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.03e-05	0.00216	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—KIT—testicular cancer	3.02e-05	0.00215	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—FGFR3—testicular cancer	2.91e-05	0.00208	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	2.91e-05	0.00208	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	2.91e-05	0.00208	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—FGFR3—testicular cancer	2.89e-05	0.00206	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—KIT—testicular cancer	2.88e-05	0.00206	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—H2AFZ—testicular cancer	2.88e-05	0.00205	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—KIT—testicular cancer	2.87e-05	0.00204	CbGpPWpGaD
Docetaxel—Hepatobiliary disease—Epirubicin—testicular cancer	2.87e-05	0.000287	CcSEcCtD
Docetaxel—Weight increased—Doxorubicin—testicular cancer	2.86e-05	0.000287	CcSEcCtD
Docetaxel—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	2.86e-05	0.00204	CbGpPWpGaD
Docetaxel—Epistaxis—Epirubicin—testicular cancer	2.86e-05	0.000287	CcSEcCtD
Docetaxel—EGFR—Direct p53 effectors—MMP2—testicular cancer	2.86e-05	0.00204	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—KIT—testicular cancer	2.86e-05	0.00203	CbGpPWpGaD
Docetaxel—Urethral disorder—Methotrexate—testicular cancer	2.85e-05	0.000286	CcSEcCtD
Docetaxel—EGFR—Signaling by PDGF—FGFR3—testicular cancer	2.85e-05	0.00203	CbGpPWpGaD
Docetaxel—Weight decreased—Doxorubicin—testicular cancer	2.85e-05	0.000285	CcSEcCtD
Docetaxel—EGFR—DAP12 signaling—KIT—testicular cancer	2.84e-05	0.00203	CbGpPWpGaD
Docetaxel—Feeling abnormal—Etoposide—testicular cancer	2.84e-05	0.000285	CcSEcCtD
Docetaxel—Nausea—Dactinomycin—testicular cancer	2.83e-05	0.000284	CcSEcCtD
Docetaxel—Agranulocytosis—Epirubicin—testicular cancer	2.83e-05	0.000284	CcSEcCtD
Docetaxel—Pneumonia—Doxorubicin—testicular cancer	2.82e-05	0.000283	CcSEcCtD
Docetaxel—Gastrointestinal pain—Etoposide—testicular cancer	2.82e-05	0.000283	CcSEcCtD
Docetaxel—Infestation—Doxorubicin—testicular cancer	2.8e-05	0.000281	CcSEcCtD
Docetaxel—Infestation NOS—Doxorubicin—testicular cancer	2.8e-05	0.000281	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—testicular cancer	2.8e-05	0.000281	CcSEcCtD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	2.8e-05	0.002	CbGpPWpGaD
Docetaxel—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	2.78e-05	0.000279	CcSEcCtD
Docetaxel—Vomiting—Ifosfamide—testicular cancer	2.78e-05	0.000278	CcSEcCtD
Docetaxel—Hypersensitivity—Cisplatin—testicular cancer	2.77e-05	0.000278	CcSEcCtD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.77e-05	0.00197	CbGpPWpGaD
Docetaxel—Renal failure—Doxorubicin—testicular cancer	2.76e-05	0.000276	CcSEcCtD
Docetaxel—Rash—Ifosfamide—testicular cancer	2.75e-05	0.000276	CcSEcCtD
Docetaxel—Dermatitis—Ifosfamide—testicular cancer	2.75e-05	0.000276	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—testicular cancer	2.75e-05	0.000276	CcSEcCtD
Docetaxel—Neuropathy peripheral—Doxorubicin—testicular cancer	2.75e-05	0.000276	CcSEcCtD
Docetaxel—Haemoglobin—Epirubicin—testicular cancer	2.73e-05	0.000274	CcSEcCtD
Docetaxel—Jaundice—Doxorubicin—testicular cancer	2.73e-05	0.000274	CcSEcCtD
Docetaxel—Stomatitis—Doxorubicin—testicular cancer	2.73e-05	0.000274	CcSEcCtD
Docetaxel—Rhinitis—Epirubicin—testicular cancer	2.73e-05	0.000274	CcSEcCtD
Docetaxel—Abdominal pain—Etoposide—testicular cancer	2.73e-05	0.000273	CcSEcCtD
Docetaxel—Body temperature increased—Etoposide—testicular cancer	2.73e-05	0.000273	CcSEcCtD
Docetaxel—Conjunctivitis—Doxorubicin—testicular cancer	2.73e-05	0.000273	CcSEcCtD
Docetaxel—Hepatitis—Epirubicin—testicular cancer	2.72e-05	0.000273	CcSEcCtD
Docetaxel—Haemorrhage—Epirubicin—testicular cancer	2.72e-05	0.000273	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—testicular cancer	2.72e-05	0.000272	CcSEcCtD
Docetaxel—Hypoaesthesia—Epirubicin—testicular cancer	2.71e-05	0.000271	CcSEcCtD
Docetaxel—Asthenia—Cisplatin—testicular cancer	2.7e-05	0.000271	CcSEcCtD
Docetaxel—Pharyngitis—Epirubicin—testicular cancer	2.7e-05	0.000271	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—testicular cancer	2.7e-05	0.000271	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—FGFR3—testicular cancer	2.7e-05	0.00192	CbGpPWpGaD
Docetaxel—Urinary tract disorder—Epirubicin—testicular cancer	2.69e-05	0.000269	CcSEcCtD
Docetaxel—Oedema peripheral—Epirubicin—testicular cancer	2.68e-05	0.000269	CcSEcCtD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	2.67e-05	0.00191	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—KIT—testicular cancer	2.67e-05	0.00191	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	2.67e-05	0.00191	CbGpPWpGaD
Docetaxel—Connective tissue disorder—Epirubicin—testicular cancer	2.67e-05	0.000268	CcSEcCtD
Docetaxel—EGFR—Signaling by NGF—KITLG—testicular cancer	2.67e-05	0.0019	CbGpPWpGaD
Docetaxel—Urethral disorder—Epirubicin—testicular cancer	2.67e-05	0.000267	CcSEcCtD
Docetaxel—Hepatobiliary disease—Doxorubicin—testicular cancer	2.65e-05	0.000266	CcSEcCtD
Docetaxel—EGFR—Signaling by EGFR—KIT—testicular cancer	2.65e-05	0.00189	CbGpPWpGaD
Docetaxel—Epistaxis—Doxorubicin—testicular cancer	2.64e-05	0.000265	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—testicular cancer	2.64e-05	0.000265	CcSEcCtD
Docetaxel—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	2.63e-05	0.00187	CbGpPWpGaD
Docetaxel—Immune system disorder—Methotrexate—testicular cancer	2.63e-05	0.000263	CcSEcCtD
Docetaxel—Visual impairment—Epirubicin—testicular cancer	2.62e-05	0.000263	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—testicular cancer	2.62e-05	0.000263	CcSEcCtD
Docetaxel—Agranulocytosis—Doxorubicin—testicular cancer	2.62e-05	0.000262	CcSEcCtD
Docetaxel—EGFR—Signaling by PDGF—KIT—testicular cancer	2.61e-05	0.00186	CbGpPWpGaD
Docetaxel—Chills—Methotrexate—testicular cancer	2.61e-05	0.000262	CcSEcCtD
Docetaxel—Nausea—Ifosfamide—testicular cancer	2.59e-05	0.00026	CcSEcCtD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	2.58e-05	0.00184	CbGpPWpGaD
Docetaxel—NR1I2—Gene Expression—H2AFZ—testicular cancer	2.58e-05	0.00184	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—KITLG—testicular cancer	2.58e-05	0.00183	CbGpPWpGaD
Docetaxel—Diarrhoea—Cisplatin—testicular cancer	2.58e-05	0.000258	CcSEcCtD
Docetaxel—Erythema multiforme—Epirubicin—testicular cancer	2.57e-05	0.000258	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—testicular cancer	2.57e-05	0.000258	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—testicular cancer	2.55e-05	0.000255	CcSEcCtD
Docetaxel—Eye disorder—Epirubicin—testicular cancer	2.54e-05	0.000255	CcSEcCtD
Docetaxel—Hypersensitivity—Etoposide—testicular cancer	2.54e-05	0.000255	CcSEcCtD
Docetaxel—Erythema—Methotrexate—testicular cancer	2.53e-05	0.000254	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—testicular cancer	2.53e-05	0.000254	CcSEcCtD
Docetaxel—Haemoglobin—Doxorubicin—testicular cancer	2.53e-05	0.000254	CcSEcCtD
Docetaxel—Cardiac disorder—Epirubicin—testicular cancer	2.52e-05	0.000253	CcSEcCtD
Docetaxel—Flushing—Epirubicin—testicular cancer	2.52e-05	0.000253	CcSEcCtD
Docetaxel—EGFR—Innate Immune System—BCL10—testicular cancer	2.52e-05	0.0018	CbGpPWpGaD
Docetaxel—Rhinitis—Doxorubicin—testicular cancer	2.52e-05	0.000253	CcSEcCtD
Docetaxel—Haemorrhage—Doxorubicin—testicular cancer	2.52e-05	0.000252	CcSEcCtD
Docetaxel—Hepatitis—Doxorubicin—testicular cancer	2.52e-05	0.000252	CcSEcCtD
Docetaxel—Hypoaesthesia—Doxorubicin—testicular cancer	2.5e-05	0.000251	CcSEcCtD
Docetaxel—Pharyngitis—Doxorubicin—testicular cancer	2.5e-05	0.000251	CcSEcCtD
Docetaxel—BCL2—Immune System—BCL10—testicular cancer	2.49e-05	0.00177	CbGpPWpGaD
Docetaxel—Urinary tract disorder—Doxorubicin—testicular cancer	2.49e-05	0.000249	CcSEcCtD
Docetaxel—Oedema peripheral—Doxorubicin—testicular cancer	2.48e-05	0.000249	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—testicular cancer	2.48e-05	0.000249	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—KIT—testicular cancer	2.47e-05	0.00176	CbGpPWpGaD
Docetaxel—Asthenia—Etoposide—testicular cancer	2.47e-05	0.000248	CcSEcCtD
Docetaxel—Connective tissue disorder—Doxorubicin—testicular cancer	2.47e-05	0.000248	CcSEcCtD
Docetaxel—Angiopathy—Epirubicin—testicular cancer	2.47e-05	0.000248	CcSEcCtD
Docetaxel—Urethral disorder—Doxorubicin—testicular cancer	2.47e-05	0.000247	CcSEcCtD
Docetaxel—Immune system disorder—Epirubicin—testicular cancer	2.46e-05	0.000246	CcSEcCtD
Docetaxel—Mediastinal disorder—Epirubicin—testicular cancer	2.45e-05	0.000246	CcSEcCtD
Docetaxel—Back pain—Methotrexate—testicular cancer	2.45e-05	0.000246	CcSEcCtD
Docetaxel—Chills—Epirubicin—testicular cancer	2.44e-05	0.000245	CcSEcCtD
Docetaxel—Pruritus—Etoposide—testicular cancer	2.44e-05	0.000245	CcSEcCtD
Docetaxel—Arrhythmia—Epirubicin—testicular cancer	2.43e-05	0.000244	CcSEcCtD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.43e-05	0.00173	CbGpPWpGaD
Docetaxel—Visual impairment—Doxorubicin—testicular cancer	2.43e-05	0.000243	CcSEcCtD
Docetaxel—EGFR—Adaptive Immune System—BCL10—testicular cancer	2.42e-05	0.00173	CbGpPWpGaD
Docetaxel—Alopecia—Epirubicin—testicular cancer	2.4e-05	0.000241	CcSEcCtD
Docetaxel—Vomiting—Cisplatin—testicular cancer	2.39e-05	0.00024	CcSEcCtD
Docetaxel—Mental disorder—Epirubicin—testicular cancer	2.38e-05	0.000239	CcSEcCtD
Docetaxel—Erythema multiforme—Doxorubicin—testicular cancer	2.38e-05	0.000239	CcSEcCtD
Docetaxel—Rash—Cisplatin—testicular cancer	2.37e-05	0.000238	CcSEcCtD
Docetaxel—Dermatitis—Cisplatin—testicular cancer	2.37e-05	0.000238	CcSEcCtD
Docetaxel—Malnutrition—Epirubicin—testicular cancer	2.37e-05	0.000238	CcSEcCtD
Docetaxel—Erythema—Epirubicin—testicular cancer	2.37e-05	0.000238	CcSEcCtD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	2.37e-05	0.00169	CbGpPWpGaD
Docetaxel—Diarrhoea—Etoposide—testicular cancer	2.36e-05	0.000237	CcSEcCtD
Docetaxel—Eye disorder—Doxorubicin—testicular cancer	2.35e-05	0.000236	CcSEcCtD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.35e-05	0.00167	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—FGFR3—testicular cancer	2.35e-05	0.00167	CbGpPWpGaD
Docetaxel—Anaemia—Methotrexate—testicular cancer	2.34e-05	0.000235	CcSEcCtD
Docetaxel—Flushing—Doxorubicin—testicular cancer	2.34e-05	0.000234	CcSEcCtD
Docetaxel—Cardiac disorder—Doxorubicin—testicular cancer	2.34e-05	0.000234	CcSEcCtD
Docetaxel—Dysgeusia—Epirubicin—testicular cancer	2.32e-05	0.000233	CcSEcCtD
Docetaxel—Back pain—Epirubicin—testicular cancer	2.29e-05	0.00023	CcSEcCtD
Docetaxel—Angiopathy—Doxorubicin—testicular cancer	2.28e-05	0.000229	CcSEcCtD
Docetaxel—Dizziness—Etoposide—testicular cancer	2.28e-05	0.000229	CcSEcCtD
Docetaxel—Muscle spasms—Epirubicin—testicular cancer	2.28e-05	0.000228	CcSEcCtD
Docetaxel—Immune system disorder—Doxorubicin—testicular cancer	2.27e-05	0.000228	CcSEcCtD
Docetaxel—Mediastinal disorder—Doxorubicin—testicular cancer	2.27e-05	0.000228	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—testicular cancer	2.27e-05	0.000227	CcSEcCtD
Docetaxel—Chills—Doxorubicin—testicular cancer	2.26e-05	0.000227	CcSEcCtD
Docetaxel—Arrhythmia—Doxorubicin—testicular cancer	2.25e-05	0.000226	CcSEcCtD
Docetaxel—Nausea—Cisplatin—testicular cancer	2.24e-05	0.000224	CcSEcCtD
Docetaxel—Alopecia—Doxorubicin—testicular cancer	2.22e-05	0.000223	CcSEcCtD
Docetaxel—Cough—Methotrexate—testicular cancer	2.21e-05	0.000221	CcSEcCtD
Docetaxel—Mental disorder—Doxorubicin—testicular cancer	2.21e-05	0.000221	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—testicular cancer	2.19e-05	0.00022	CcSEcCtD
Docetaxel—Vomiting—Etoposide—testicular cancer	2.19e-05	0.00022	CcSEcCtD
Docetaxel—Erythema—Doxorubicin—testicular cancer	2.19e-05	0.00022	CcSEcCtD
Docetaxel—Malnutrition—Doxorubicin—testicular cancer	2.19e-05	0.00022	CcSEcCtD
Docetaxel—Anaemia—Epirubicin—testicular cancer	2.19e-05	0.00022	CcSEcCtD
Docetaxel—Rash—Etoposide—testicular cancer	2.17e-05	0.000218	CcSEcCtD
Docetaxel—Dermatitis—Etoposide—testicular cancer	2.17e-05	0.000218	CcSEcCtD
Docetaxel—Headache—Etoposide—testicular cancer	2.16e-05	0.000217	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—testicular cancer	2.15e-05	0.000216	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—testicular cancer	2.15e-05	0.000216	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—testicular cancer	2.15e-05	0.000216	CcSEcCtD
Docetaxel—GHRHR—Signaling Pathways—KIT—testicular cancer	2.15e-05	0.00153	CbGpPWpGaD
Docetaxel—Dysgeusia—Doxorubicin—testicular cancer	2.15e-05	0.000215	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	2.14e-05	0.000215	CcSEcCtD
Docetaxel—Syncope—Epirubicin—testicular cancer	2.12e-05	0.000213	CcSEcCtD
Docetaxel—Leukopenia—Epirubicin—testicular cancer	2.12e-05	0.000213	CcSEcCtD
Docetaxel—Back pain—Doxorubicin—testicular cancer	2.12e-05	0.000213	CcSEcCtD
Docetaxel—Muscle spasms—Doxorubicin—testicular cancer	2.11e-05	0.000211	CcSEcCtD
Docetaxel—Palpitations—Epirubicin—testicular cancer	2.09e-05	0.00021	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—testicular cancer	2.08e-05	0.000209	CcSEcCtD
Docetaxel—Loss of consciousness—Epirubicin—testicular cancer	2.08e-05	0.000209	CcSEcCtD
Docetaxel—Cough—Epirubicin—testicular cancer	2.07e-05	0.000207	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—testicular cancer	2.07e-05	0.000207	CcSEcCtD
Docetaxel—Convulsion—Epirubicin—testicular cancer	2.05e-05	0.000206	CcSEcCtD
Docetaxel—Infection—Methotrexate—testicular cancer	2.05e-05	0.000206	CcSEcCtD
Docetaxel—Nausea—Etoposide—testicular cancer	2.05e-05	0.000205	CcSEcCtD
Docetaxel—Hypertension—Epirubicin—testicular cancer	2.04e-05	0.000205	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—testicular cancer	2.03e-05	0.000203	CcSEcCtD
Docetaxel—Anaemia—Doxorubicin—testicular cancer	2.03e-05	0.000203	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—testicular cancer	2.02e-05	0.000203	CcSEcCtD
Docetaxel—Myalgia—Epirubicin—testicular cancer	2.02e-05	0.000202	CcSEcCtD
Docetaxel—Chest pain—Epirubicin—testicular cancer	2.02e-05	0.000202	CcSEcCtD
Docetaxel—Arthralgia—Epirubicin—testicular cancer	2.02e-05	0.000202	CcSEcCtD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.01e-05	0.00143	CbGpPWpGaD
Docetaxel—Skin disorder—Methotrexate—testicular cancer	2.01e-05	0.000201	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	2e-05	0.000201	CcSEcCtD
Docetaxel—EGFR—Signaling by NGF—FGFR3—testicular cancer	1.98e-05	0.00141	CbGpPWpGaD
Docetaxel—Dry mouth—Epirubicin—testicular cancer	1.97e-05	0.000198	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—testicular cancer	1.97e-05	0.000197	CcSEcCtD
Docetaxel—Syncope—Doxorubicin—testicular cancer	1.97e-05	0.000197	CcSEcCtD
Docetaxel—Leukopenia—Doxorubicin—testicular cancer	1.96e-05	0.000197	CcSEcCtD
Docetaxel—Confusional state—Epirubicin—testicular cancer	1.95e-05	0.000195	CcSEcCtD
Docetaxel—EGFR—Signaling Pathways—INSL3—testicular cancer	1.95e-05	0.00139	CbGpPWpGaD
Docetaxel—Palpitations—Doxorubicin—testicular cancer	1.94e-05	0.000194	CcSEcCtD
Docetaxel—Oedema—Epirubicin—testicular cancer	1.93e-05	0.000194	CcSEcCtD
Docetaxel—Anaphylactic shock—Epirubicin—testicular cancer	1.93e-05	0.000194	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—testicular cancer	1.93e-05	0.000194	CcSEcCtD
Docetaxel—Loss of consciousness—Doxorubicin—testicular cancer	1.93e-05	0.000193	CcSEcCtD
Docetaxel—Infection—Epirubicin—testicular cancer	1.92e-05	0.000193	CcSEcCtD
Docetaxel—BCL2—Innate Immune System—FGFR3—testicular cancer	1.91e-05	0.00136	CbGpPWpGaD
Docetaxel—Cough—Doxorubicin—testicular cancer	1.91e-05	0.000192	CcSEcCtD
Docetaxel—Shock—Epirubicin—testicular cancer	1.9e-05	0.000191	CcSEcCtD
Docetaxel—Convulsion—Doxorubicin—testicular cancer	1.9e-05	0.00019	CcSEcCtD
Docetaxel—Nervous system disorder—Epirubicin—testicular cancer	1.9e-05	0.00019	CcSEcCtD
Docetaxel—Thrombocytopenia—Epirubicin—testicular cancer	1.89e-05	0.00019	CcSEcCtD
Docetaxel—Hypertension—Doxorubicin—testicular cancer	1.89e-05	0.00019	CcSEcCtD
Docetaxel—Tachycardia—Epirubicin—testicular cancer	1.89e-05	0.000189	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.88e-05	0.000189	CcSEcCtD
Docetaxel—Skin disorder—Epirubicin—testicular cancer	1.88e-05	0.000188	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—testicular cancer	1.87e-05	0.000187	CcSEcCtD
Docetaxel—Chest pain—Doxorubicin—testicular cancer	1.87e-05	0.000187	CcSEcCtD
Docetaxel—Myalgia—Doxorubicin—testicular cancer	1.87e-05	0.000187	CcSEcCtD
Docetaxel—Arthralgia—Doxorubicin—testicular cancer	1.87e-05	0.000187	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—testicular cancer	1.85e-05	0.000186	CcSEcCtD
Docetaxel—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.85e-05	0.00132	CbGpPWpGaD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.85e-05	0.000186	CcSEcCtD
Docetaxel—Anorexia—Epirubicin—testicular cancer	1.84e-05	0.000185	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—testicular cancer	1.84e-05	0.000185	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—testicular cancer	1.84e-05	0.000184	CcSEcCtD
Docetaxel—Dry mouth—Doxorubicin—testicular cancer	1.82e-05	0.000183	CcSEcCtD
Docetaxel—EGFR—Signaling by NGF—KIT—testicular cancer	1.82e-05	0.0013	CbGpPWpGaD
Docetaxel—Dyspepsia—Methotrexate—testicular cancer	1.82e-05	0.000182	CcSEcCtD
Docetaxel—Hypotension—Epirubicin—testicular cancer	1.81e-05	0.000181	CcSEcCtD
Docetaxel—Confusional state—Doxorubicin—testicular cancer	1.8e-05	0.000181	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—testicular cancer	1.8e-05	0.00018	CcSEcCtD
Docetaxel—Oedema—Doxorubicin—testicular cancer	1.79e-05	0.000179	CcSEcCtD
Docetaxel—Anaphylactic shock—Doxorubicin—testicular cancer	1.79e-05	0.000179	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—testicular cancer	1.78e-05	0.000179	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—testicular cancer	1.78e-05	0.000179	CcSEcCtD
Docetaxel—TUBB2B—Metabolism of proteins—MMP2—testicular cancer	1.78e-05	0.00127	CbGpPWpGaD
Docetaxel—TUBB6—Metabolism of proteins—MMP2—testicular cancer	1.78e-05	0.00127	CbGpPWpGaD
Docetaxel—Infection—Doxorubicin—testicular cancer	1.78e-05	0.000178	CcSEcCtD
Docetaxel—Pain—Methotrexate—testicular cancer	1.77e-05	0.000177	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.76e-05	0.000177	CcSEcCtD
Docetaxel—Shock—Doxorubicin—testicular cancer	1.76e-05	0.000176	CcSEcCtD
Docetaxel—BCL2—Innate Immune System—KIT—testicular cancer	1.76e-05	0.00125	CbGpPWpGaD
Docetaxel—Nervous system disorder—Doxorubicin—testicular cancer	1.75e-05	0.000176	CcSEcCtD
Docetaxel—Thrombocytopenia—Doxorubicin—testicular cancer	1.75e-05	0.000176	CcSEcCtD
Docetaxel—Insomnia—Epirubicin—testicular cancer	1.75e-05	0.000175	CcSEcCtD
Docetaxel—Tachycardia—Doxorubicin—testicular cancer	1.75e-05	0.000175	CcSEcCtD
Docetaxel—Skin disorder—Doxorubicin—testicular cancer	1.74e-05	0.000174	CcSEcCtD
Docetaxel—Paraesthesia—Epirubicin—testicular cancer	1.74e-05	0.000174	CcSEcCtD
Docetaxel—Dyspnoea—Epirubicin—testicular cancer	1.72e-05	0.000173	CcSEcCtD
Docetaxel—Somnolence—Epirubicin—testicular cancer	1.72e-05	0.000172	CcSEcCtD
Docetaxel—TUBB3—Metabolism of proteins—MMP2—testicular cancer	1.72e-05	0.00122	CbGpPWpGaD
Docetaxel—Anorexia—Doxorubicin—testicular cancer	1.7e-05	0.000171	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—testicular cancer	1.7e-05	0.000171	CcSEcCtD
Docetaxel—Dyspepsia—Epirubicin—testicular cancer	1.7e-05	0.000171	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—testicular cancer	1.69e-05	0.000169	CcSEcCtD
Docetaxel—Decreased appetite—Epirubicin—testicular cancer	1.68e-05	0.000169	CcSEcCtD
Docetaxel—Hypotension—Doxorubicin—testicular cancer	1.67e-05	0.000168	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Epirubicin—testicular cancer	1.67e-05	0.000167	CcSEcCtD
Docetaxel—Fatigue—Epirubicin—testicular cancer	1.67e-05	0.000167	CcSEcCtD
Docetaxel—TUBB2A—Metabolism of proteins—MMP2—testicular cancer	1.66e-05	0.00119	CbGpPWpGaD
Docetaxel—Pain—Epirubicin—testicular cancer	1.65e-05	0.000166	CcSEcCtD
Docetaxel—Constipation—Epirubicin—testicular cancer	1.65e-05	0.000166	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—testicular cancer	1.63e-05	0.000164	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—testicular cancer	1.63e-05	0.000164	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.63e-05	0.000163	CcSEcCtD
Docetaxel—TUBB1—Metabolism of proteins—MMP2—testicular cancer	1.63e-05	0.00116	CbGpPWpGaD
Docetaxel—Insomnia—Doxorubicin—testicular cancer	1.62e-05	0.000162	CcSEcCtD
Docetaxel—Paraesthesia—Doxorubicin—testicular cancer	1.61e-05	0.000161	CcSEcCtD
Docetaxel—Dyspnoea—Doxorubicin—testicular cancer	1.59e-05	0.00016	CcSEcCtD
Docetaxel—Feeling abnormal—Epirubicin—testicular cancer	1.59e-05	0.00016	CcSEcCtD
Docetaxel—Somnolence—Doxorubicin—testicular cancer	1.59e-05	0.000159	CcSEcCtD
Docetaxel—Gastrointestinal pain—Epirubicin—testicular cancer	1.58e-05	0.000159	CcSEcCtD
Docetaxel—Dyspepsia—Doxorubicin—testicular cancer	1.57e-05	0.000158	CcSEcCtD
Docetaxel—Decreased appetite—Doxorubicin—testicular cancer	1.55e-05	0.000156	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.54e-05	0.000155	CcSEcCtD
Docetaxel—Fatigue—Doxorubicin—testicular cancer	1.54e-05	0.000155	CcSEcCtD
Docetaxel—SLCO1B3—Metabolism—HPGDS—testicular cancer	1.53e-05	0.00109	CbGpPWpGaD
Docetaxel—Pain—Doxorubicin—testicular cancer	1.53e-05	0.000153	CcSEcCtD
Docetaxel—Constipation—Doxorubicin—testicular cancer	1.53e-05	0.000153	CcSEcCtD
Docetaxel—Abdominal pain—Epirubicin—testicular cancer	1.53e-05	0.000153	CcSEcCtD
Docetaxel—Body temperature increased—Epirubicin—testicular cancer	1.53e-05	0.000153	CcSEcCtD
Docetaxel—EGFR—Innate Immune System—KITLG—testicular cancer	1.52e-05	0.00108	CbGpPWpGaD
Docetaxel—Hypersensitivity—Methotrexate—testicular cancer	1.52e-05	0.000153	CcSEcCtD
Docetaxel—BCL2—Immune System—KITLG—testicular cancer	1.5e-05	0.00107	CbGpPWpGaD
Docetaxel—Asthenia—Methotrexate—testicular cancer	1.48e-05	0.000149	CcSEcCtD
Docetaxel—Feeling abnormal—Doxorubicin—testicular cancer	1.47e-05	0.000148	CcSEcCtD
Docetaxel—EGFR—Immune System—BCL10—testicular cancer	1.47e-05	0.00105	CbGpPWpGaD
Docetaxel—Gastrointestinal pain—Doxorubicin—testicular cancer	1.46e-05	0.000147	CcSEcCtD
Docetaxel—EGFR—Adaptive Immune System—KITLG—testicular cancer	1.46e-05	0.00104	CbGpPWpGaD
Docetaxel—Pruritus—Methotrexate—testicular cancer	1.46e-05	0.000147	CcSEcCtD
Docetaxel—TUBB4A—Metabolism of proteins—MMP2—testicular cancer	1.46e-05	0.00104	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—MMP2—testicular cancer	1.46e-05	0.00104	CbGpPWpGaD
Docetaxel—Hypersensitivity—Epirubicin—testicular cancer	1.42e-05	0.000143	CcSEcCtD
Docetaxel—Body temperature increased—Doxorubicin—testicular cancer	1.41e-05	0.000142	CcSEcCtD
Docetaxel—Abdominal pain—Doxorubicin—testicular cancer	1.41e-05	0.000142	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—testicular cancer	1.41e-05	0.000142	CcSEcCtD
Docetaxel—Asthenia—Epirubicin—testicular cancer	1.39e-05	0.000139	CcSEcCtD
Docetaxel—Pruritus—Epirubicin—testicular cancer	1.37e-05	0.000137	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—testicular cancer	1.37e-05	0.000137	CcSEcCtD
Docetaxel—TUBB4B—Metabolism of proteins—MMP2—testicular cancer	1.34e-05	0.000952	CbGpPWpGaD
Docetaxel—Diarrhoea—Epirubicin—testicular cancer	1.32e-05	0.000133	CcSEcCtD
Docetaxel—Hypersensitivity—Doxorubicin—testicular cancer	1.32e-05	0.000132	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—testicular cancer	1.31e-05	0.000132	CcSEcCtD
Docetaxel—Rash—Methotrexate—testicular cancer	1.3e-05	0.000131	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—testicular cancer	1.3e-05	0.00013	CcSEcCtD
Docetaxel—Headache—Methotrexate—testicular cancer	1.29e-05	0.00013	CcSEcCtD
Docetaxel—Asthenia—Doxorubicin—testicular cancer	1.28e-05	0.000129	CcSEcCtD
Docetaxel—Dizziness—Epirubicin—testicular cancer	1.28e-05	0.000128	CcSEcCtD
Docetaxel—Pruritus—Doxorubicin—testicular cancer	1.27e-05	0.000127	CcSEcCtD
Docetaxel—Vomiting—Epirubicin—testicular cancer	1.23e-05	0.000123	CcSEcCtD
Docetaxel—Nausea—Methotrexate—testicular cancer	1.23e-05	0.000123	CcSEcCtD
Docetaxel—Diarrhoea—Doxorubicin—testicular cancer	1.22e-05	0.000123	CcSEcCtD
Docetaxel—Rash—Epirubicin—testicular cancer	1.22e-05	0.000122	CcSEcCtD
Docetaxel—Dermatitis—Epirubicin—testicular cancer	1.22e-05	0.000122	CcSEcCtD
Docetaxel—Headache—Epirubicin—testicular cancer	1.21e-05	0.000121	CcSEcCtD
Docetaxel—Dizziness—Doxorubicin—testicular cancer	1.18e-05	0.000119	CcSEcCtD
Docetaxel—Nausea—Epirubicin—testicular cancer	1.15e-05	0.000115	CcSEcCtD
Docetaxel—Vomiting—Doxorubicin—testicular cancer	1.14e-05	0.000114	CcSEcCtD
Docetaxel—EGFR—Innate Immune System—FGFR3—testicular cancer	1.13e-05	0.000806	CbGpPWpGaD
Docetaxel—Rash—Doxorubicin—testicular cancer	1.13e-05	0.000113	CcSEcCtD
Docetaxel—Dermatitis—Doxorubicin—testicular cancer	1.13e-05	0.000113	CcSEcCtD
Docetaxel—Headache—Doxorubicin—testicular cancer	1.12e-05	0.000112	CcSEcCtD
Docetaxel—BCL2—Immune System—FGFR3—testicular cancer	1.11e-05	0.000794	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—STK11—testicular cancer	1.11e-05	0.000792	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—FGFR3—testicular cancer	1.09e-05	0.000774	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—HPGDS—testicular cancer	1.08e-05	0.000771	CbGpPWpGaD
Docetaxel—Nausea—Doxorubicin—testicular cancer	1.06e-05	0.000107	CcSEcCtD
Docetaxel—CYP1B1—Metabolism—HPGDS—testicular cancer	1.05e-05	0.000746	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MMP2—testicular cancer	1.04e-05	0.000743	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—KIT—testicular cancer	1.04e-05	0.00074	CbGpPWpGaD
Docetaxel—BCL2—Immune System—KIT—testicular cancer	1.02e-05	0.000729	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—KIT—testicular cancer	9.98e-06	0.000711	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—HPGDS—testicular cancer	9.52e-06	0.000678	CbGpPWpGaD
Docetaxel—ABCC1—Disease—H2AFZ—testicular cancer	9.44e-06	0.000673	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—HPGDS—testicular cancer	9.44e-06	0.000672	CbGpPWpGaD
Docetaxel—EGFR—Disease—H2AFZ—testicular cancer	8.9e-06	0.000634	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KITLG—testicular cancer	8.87e-06	0.000632	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KITLG—testicular cancer	8.69e-06	0.000619	CbGpPWpGaD
Docetaxel—EGFR—Disease—KITLG—testicular cancer	8.19e-06	0.000583	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—STK11—testicular cancer	7.86e-06	0.00056	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—STK11—testicular cancer	7.6e-06	0.000542	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—STK11—testicular cancer	6.92e-06	0.000493	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—STK11—testicular cancer	6.86e-06	0.000489	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—HPGDS—testicular cancer	6.82e-06	0.000486	CbGpPWpGaD
Docetaxel—EGFR—Immune System—FGFR3—testicular cancer	6.59e-06	0.00047	CbGpPWpGaD
Docetaxel—ABCC1—Disease—FGFR3—testicular cancer	6.46e-06	0.00046	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—H2AFZ—testicular cancer	6.23e-06	0.000444	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—STK11—testicular cancer	6.2e-06	0.000441	CbGpPWpGaD
Docetaxel—EGFR—Disease—FGFR3—testicular cancer	6.08e-06	0.000434	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KIT—testicular cancer	6.05e-06	0.000431	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KIT—testicular cancer	5.93e-06	0.000422	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KITLG—testicular cancer	5.73e-06	0.000409	CbGpPWpGaD
Docetaxel—EGFR—Disease—KIT—testicular cancer	5.59e-06	0.000398	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—HPGDS—testicular cancer	5.15e-06	0.000367	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—STK11—testicular cancer	4.96e-06	0.000353	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FGFR3—testicular cancer	4.26e-06	0.000304	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KIT—testicular cancer	3.91e-06	0.000279	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—STK11—testicular cancer	3.74e-06	0.000267	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—HPGDS—testicular cancer	3.17e-06	0.000226	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—STK11—testicular cancer	2.3e-06	0.000164	CbGpPWpGaD
